Abstract
Spondyloarthritis (SpA) and inflammatory bowel diseases (IBD) are chronic inflammatory diseases characterized by an aberrant immune response and inflammation with a key role for TNF in their pathogenesis. Accordingly, TNF-inhibiting therapy (TNFi) has dramatically improved the management of these diseases. However, about 30% of patients discontinue TNFi for lack of response, loss of response, and side effects and/or adverse events. Thus, the possibility to identify in advance those patients who will have a good response to TNFi would be extremely beneficial. The aim of this study was to investigate differences between males and females with either SpA or IBD in response to TNFi molecules, i.e., infliximab (IFX) and adalimumab (ADA), considering the reasons for TNFi withdraw. Data of 594 patients, 349 with IBD (M/F: 194/155) and 245 with SpA (M/F: 123/122), previously unexposed to TNFi, were collected. In the IBD group, the rate of female patients discontinuing ADA was significantly higher than that of male patients (p = 0.03). No difference emerged according to the distribution of reason for discontinuation. Otherwise, a similar discontinuation rate between female and male patients receiving IFX therapy was observed. In the SpA group, the overall discontinuation rate was not different between males and females both for ADA and IFX. However, in patients treated with ADA, males interrupted therapy more frequently than females due to lack of response (p = 0.03). In conclusion, the assessment of sex differences in TNFi response could help physicians personalize the therapeutic approach in a sex-oriented perspective.
Introduction
Chronic inflammatory diseases are a group of pathologies with different clinical features, but with shared pathogenetic mechanisms leading to a not resolving inflammation. SpA refers to a group of inflammatory diseases that cause arthritis, consisting of predominantly axial or peripheral clinical manifestations (). IBD is a group of chronic systemic diseases causing inflammation of the gastrointestinal tract. Ulcerative colitis affects only the large bowel () and Crohn’s disease can involve the whole gastrointestinal tract (). Several lines of evidence support a key pathogenic role for TNF in perpetuating chronic inflammation of SpA and IBD. In SpA, increased TNFα in synovial tissues and sacroiliac joints, associated with bony destruction, osteoproliferation, and synovitis, were found (; ). In IBD, elevated expression of TNF was detected in involved colonic tissue (; ). Moreover, high levels of TNF in serum and in the intestinal lamina propria were found to correlate with disease activity (, ; ). The pathogenic effect of TNF is related to its ability to disrupt the integrity of intestinal epithelium and affect the activity of regulatory T cells and regulatory macrophages (). In the treatment of SpA and IBD, corticosteroids and immunosuppressive agents are used to induce and maintain long-term remission. When these drugs fail to achieve sufficient disease control, biologic agents are used. Indeed, the introduction of TNFi has dramatically improved the management of SpA and IBD. However, about 30% of patients do not respond to TNFi at all or lose their initial response over time. In the time frame from initiation of therapy until response can be judged, non-responding patients suffer from uncontrolled disease. In addition, some patients have to discontinue TNFi because of severe side effects and/or adverse events (; ). Thus, the ability to identify in advance those patients who will have a good response to TNFi would be extremely beneficial.
Gender medicine deals with studying how diseases differ between men and women in terms of prevention, clinical signs, prognosis, and therapeutic approach (). In particular, there are sex-related differences in pharmacokinetics and pharmacodynamics, with evident consequence in the efficacy and side effects and/or adverse events of various drugs in the two sexes. This evidence should be considered before starting any therapy.
Of note, both SpA and IBD are characterized by the presence of sex differences in their onset, progression and response to therapy (,; ). Regarding TNFi, differences between males and females in response to these drugs have recently been suggested, with males responding better than females (,; ; ,). However, the relationship between sex and response to TNFi in SpA and IBD is far to be fully elucidated. Hence, aim of this study was to better investigate differences between males and females with either SpA or IBD in response to two TNFi molecules that dominate the biologic management of these diseases, i.e., IFX and ADA, taking into account the most common reasons for TNFi withdraw, including lack of response, loss of response at follow-up, and side effects and/or adverse events.
Materials and Methods
This was a retrospective study enrolling IBD and SpA patients in 7 centers (4 Rheumatology Units and 3 Gastroenterology Units). In each center, diagnostic criteria recommended by International guidelines were followed (; ; ; ). Only patients receiving TNFi therapy (ADA; IFX) were considered. Clinical records were reviewed and data were anonymously collected in a specific electronic database. For statistical analyses, the Mann-Whitney U-test, Chi-square test and the Fisher’s exact test were used. The significance level was fixed at p < 0.05. This study was carried out in accordance with the recommendations of the Declaration of Helsinki and the ethics committee of Azienda Ospedaliera San Camillo Forlanini approved the study (2006/CE Lazio 1).
Results
Data of 594 patients, 349 with IBD (M/F: 194/155) and 245 with SpA (M/F: 123/122) were collected.
Inflammatory Bowel Diseases
Clinical characteristics of IBD patients according to sex are shown in Table 1. There were 155 females (mean age 47 ± 16 years and disease duration 133 ± 110 months) and 194 males (mean age 46 ± 14 years and disease duration 144 ± 104 months) with IBD.
Table 1
| Patients | IBD | P | SpA | P | ||
|---|---|---|---|---|---|---|
| Sex | F | M | F | M | ||
| Number, n | 155 | 194 | 122 | 123 | ||
| Age, years (mean ± SD) | 47 ± 16 | 46 ± 14 | 0.59 | 53 ± 14 | 55 ± 13 | 0.39 |
| Disease duration, months (mean ± SD) | 133 ± 110 | 144 ± 104 | 0.16 | 52 ± 71 | 64 ± 85 | 0.88 |
| Adalimumab, n (%) | 77/155 (50%) | 85/194 (44%) | 0.28 | 93/122 (76.3%) | 76/123 (61.8%) | 0.02 |
| Treatment discontinuation, n (%) | 17/77 (22%) | 8/85 (9%) | 0.03 | 26/93 (28%) | 16/76 (21%) | 0.37 |
| Lack of efficacy, n (%) | 6/17 (35.3%) | 2/8 (25%) | 1.0 | 7/26 (27%) | 10/16 (62.5%) | 0.03 |
| Loss of efficacy, n (%) | 7/17 (41.2%) | 3/8 (37.5%) | 1.0 | 14/26 (53.8%) | 6/16 (37.5%) | 0.35 |
| Side/adverse effects, n (%) | 4/17 (23.5%) | 3/8 (37.5%) | 0.6 | 5/26 (19.2%) | 0/16 (0%) | 0.14 |
| Infliximab, n (%) | 78/155 (50%) | 109/194 (56%) | 0.28 | 29/122 (23.7%) | 47/123 (38.2%) | 0.02 |
| Infliximab discontinuation, n (%) | 25/78 (32%) | 30/109 (27.5%) | 0.52 | 18/29 (62%) | 22/47 (47%) | 0.24 |
| Lack of efficacy, n (%) | 8/25 (32%) | 3/30 (10%) | 0.09 | 6/18 (33.3%) | 8/22 (36.4%) | 1.0 |
| Loss of efficacy, n (%) | 9/25 (36%) | 16/30 (53.3%) | 0.28 | 4/18 (22.2%) | 4/22 (18.2%) | 1.0 |
| Side/adverse effects, n (%) | 8/25(32%) | 11/30 (36.7%) | 0.78 | 8/18 (44.5%) | 10/22 (45.4%) | 1.0 |
Clinical characteristics of patients with IBD and SpA according to sex.
Bolded values refer to significant values (P < 0.05).
Overall, 80 (22.9%; 95% CI = 18.8–27.6) patients discontinued therapy for any reason. Among the female patients, 77 (50%) were treated with ADA and 78 (50%) with IFX. The rate (17/77, 22%) of female patients discontinuing ADA was not significantly different to that discontinuing IFX (25/78, 32%). Among the 194 male patients, 85 (44%) patients were treated with ADA and 109 (56%) with IFX. Of note, the rate (30/109, 27.5%) of male patients discontinuing IFX was significantly (p = 0.0018) higher than that discontinuing ADA (8/85, 9%). This observation suggested a better success of ADA than IFX treatment in male patients with IBD.
When comparing data according to sex (Table 1), the overall rate of female patients discontinuing ADA (17/77, 22%) was significantly (p = 0.03) higher than that of male patients (8/85, 9%). However, no difference emerged according to the distribution of reason for discontinuation, i.e., lack of response, loss of response at follow-up, and side effects and/or adverse events. No significant differences between female and male patients were detected for IFX discontinuation.
Analyzing treatment duration before drug discontinuation (Figure 1), we observed that this parameter was significantly shorter in female than male patients for IFX (median 6 months, range 1–50 months vs. 17 months, range 1–146 months, p = 0.003) but not for ADA (median 8 months, range 2–48 months vs. 15 months, range 2–35 months).
FIGURE 1
Spondyloarthritis
Clinical characteristics of SpA patients according to sex are shown in Table 1.
We enrolled 122 females (mean age 53 ± 14 years and disease duration 52 ± 71 months) and 123 males (mean age 55 ± 13 years and disease duration 64 ± 85 months) with SpA.
Overall, 82 (33.5%; 95% CI = 27.9–39.6) patients discontinued therapy for any reason. Among female patients, 93 patients (76.3%) were treated with ADA and 29 (23.7%) with IFX. The rate of female patients discontinuing IFX was significantly higher than that discontinuing ADA (18/29, 62% vs. 26/93, 28%, p = 0.002). Among male patients, 76 (61.8%) were treated with ADA and 47 (38.2%) with IFX. The rate of male patients discontinuing IFX was significantly higher than that discontinuing ADA (22/47, 47% vs. 16/76, 21%, p = 0.005). This observation suggested a better success of ADA than IFX treatment in both female and male patients with SpA.
Considering sex differences (Table 1), regarding the choice of TNFi a higher percentage of females than males started ADA and a higher percentage of males than females started IFX (p = 0.02 in both cases). The overall discontinuation rate was not different between males and females, however in the ADA therapy group male patients interrupted therapy more frequently than females due to lack of response (10/16, 62.5% vs. 7/26, 27%, p = 0.03). As shown in Figure 1, the median of therapy duration before interruption was similar between female and male patients, for both IFX (24 months, range 1–66 months vs. 19 months, range 4–150 months) and ADA (12 months, range 3–90 months vs. 12 months, range 3–72 months).
Discussion
To investigate whether differences exist between males and females as concerned the response to IFX and ADA, we considered patients with different chronic inflammatory diseases, such as IBD and SpA, disaggregating data for sex and type of drug. Overall, in the IBD patients, we observed that female sex appeared to be a negative predictive factor for ADA response, confirming previous reported studies (; ; ). In some studies (; ) ADA discontinuation was observed to be associated to a higher risk in female than in male patients for skin reactions, infections, and arthralgia. In contrast, we did not find any difference between males and females regarding adverse effects underlying ADA discontinuation. Considering that women have a stronger innate and acquired immune response than men, thus being more resistant to infections but more susceptible to autoimmune and allergic reactions (), the controversial data regarding adverse events needs to be further investigated in a larger patient population. Regarding IFX treatment, no significant differences between female and male patients were detected for drug discontinuation. However, accordingly to Olivera et al. (), we observed that, among patients discontinuing IFX, females stayed on IFX for a significantly shorter period compared to males. Interestingly, carrying out a head to head comparison of the two TNFi investigated, ADA seems to achieve better results than IFX in males, whereas no differences were observed within the female population.
In the SpA patients, ADA represents the mainstay of management independently from sex. Interestingly, more female patients were treated with ADA whereas more male patients were treated with IFX. No differences for ADA or IFX discontinuation were detected between males and females. Regarding the reason for ADA discontinuation, lack of drug efficacy is more frequent in males than in females. Our data are in contrast with those reported by literature showing that treatment efficacy of TNFi in SpA was lower in women compared to men and that switching TNFi treatment was more frequent in female than in male patients (,). In this regard, one important limitation of our retrospective study is the lack of information regarding a range of variables able to impact TNFi response, such as smoking, body mass index, and glucocorticoid use. Hence, a larger prospective study, taking into account all these variables, is strongly needed to better define the role of sex in TNFi response.
Conclusion
In conclusion, our data found that patients with chronic inflammatory diseases may have different outcomes linked to the type of drug and the disease, as well as to the sex. In this context, the assessment of sex differences in TNFi response could help physicians personalize the therapeutic approach in a sex-oriented perspective in different inflammatory diseases.
Statements
Author contributions
BL, AZ, MS, MC, AM, APD, RL, PS, and LR contributed to patient enrolment, data collection, and interpretation. VB provided intellectual input throughout the study. MP and EO provided important contribution to the conception of the work as well manuscript writing. All the authors read and approved the final manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abbreviations
- ADA
adalimumab
- IBD
inflammatory bowel disease
- IFX
infliximab
- SpA
spondyloarthritis
- TNFi
TNF-inhibiting therapy
References
1
BaggioG.CorsiniA.FloreaniA.GianniniS.ZagonelV. (2013). Gender medicine: a task for the third millennium.Clin. Chem. Lab. Med.51713–727. 10.1515/cclm-2012-0849
2
ChouC.-T. (2013). How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis.Clin. Dev. Immunol.2013:369202. 10.1155/2013/369202
3
DionneS.HiscottJ.D’AgataI.DuhaimeA.SeidmanE. G. (1997). Quantitative PCR analysis of TNF-α and IL-1β mRNA levels in pediatric IBD mucosal biopsies.Dig. Dis. Sci.421557–1566. 10.1023/A:1018895500721
4
DubashS.McGonagleD.Marzo-OrtegaH. (2018). New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice.Ther. Adv. Chronic Dis.977–87. 10.1177/2040622317743486
5
GomollonF.DignassA.AnneseV.TilgH.Van AsscheG.LindsayJ. O.et al (2017). Third European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management.J. Crohns Colitis113–25. 10.1093/ecco-jcc/jjw168
6
Gonzalez-LamaY.Fernandez-BlancoI.Lopez-SanRomanA.TaxoneraC.CasisB.TaberneroS.et al (2008a). Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.Hepatogastroenterology551609–1614.
7
Gonzalez-LamaY.Lopez-San RomanA.Marin-JimenezI.CasisB.VeraI.BermejoF.et al (2008b). Open-label infliximab therapy in Crohn’s disease: a long-term multicenter study of efficacy, safety and predictors of response.Gastroenterol. Hepatol.31421–426.
8
GossecL.SmolenJ. S.RamiroS.de WitM.CutoloM.DougadosM.et al (2016). European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.Ann. Rheum. Dis.75499–510. 10.1136/annrheumdis-2015-208337
9
KaldenJ. R.Schulze-KoopsH. (2017). Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.Nat. Rev. Rheumatol.13707–718. 10.1038/nrrheum.2017.187
10
KleinS. L.FlanaganK. L. (2016). Sex differences in immune responses.Nat. Rev. Immunol.16626–638. 10.1038/nri.2016.90
11
LopetusoL. R.GerardiV.PapaV.ScaldaferriF.RapacciniG. L.GasbarriniA.et al (2017). Can we predict the efficacy of anti-TNF-alpha agents?Int. J. Mol. Sci.18:E1973. 10.3390/ijms18091973
12
MaedaM.WatanabeN.NedaH.YamauchiN.OkamotoT.SasakiH.et al (1992). Serum tumor necrosis factor activity in inflammatory bowel disease.Immunopharmacol. Immunotoxicol.14451–461. 10.3109/08923979209005404
13
MagroF.GionchettiP.EliakimR.ArdizzoneS.ArmuzziA.Barreiro-de AcostaM.et al (2017). Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders.J. Crohns Colitis11649–670. 10.1093/ecco-jcc/jjx008
14
MatsudaR.KoideT.TokoroC.YamamotoT.GodaiT.MorohashiT.et al (2009). Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease.Inflamm. Bowel Dis.15328–334. 10.1002/ibd.20759
15
MurchS. H.BraeggerC. P.Walker-SmithJ. A.MacDonaldT. T. (1993). Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.Gut341705–1709. 10.1136/gut.34.12.1705
16
MurchS. H.LamkinV. A.SavageM. O.Walker-SmithJ. A.MacDonaldT. T. (1991). Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.Gut32913–917. 10.1136/gut.32.8.913
17
OliveraP.ThirietL.LucA.BaumannC.DaneseS.Peyrin-BirouletL. (2017). Treatment persistence for infliximab versus adalimumab in Crohn’s disease: a 14-year single-center experience.Inflamm. Bowel Dis.23976–985. 10.1097/MIB.0000000000001072
18
ProftF.PoddubnyyD. (2018). Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria.Ther. Adv. Musculoskelet. Dis.10129–139. 10.1177/1759720X18773726
19
RusmanT.Ten WoldeS.EuserS. M.van der PloegT.van HallO.van der Horst-BruinsmaI. E. (2018a). Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice.Int. J. Rheum. Dis.21836–842. 10.1111/1756-185X.13271
20
RusmanT.van VollenhovenR. F.van der Horst-BruinsmaI. E. (2018b). Gender differences in axial spondyloarthritis: women are not so lucky.Curr. Rheumatol. Rep.20:35. 10.1007/s11926-018-0744-2
21
ShahS. C.KhaliliH.Gower-RousseauC.OlenO.BenchimolE. I.LyngeE.et al (2018). Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from Western countries.Gastroenterology551079–1089.e3. 10.1053/j.gastro.2018.06.043
22
ŚlebiodaT. J.KmiećZ. (2014). Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease.Mediators Inflamm.2014:325129. 10.1155/2014/325129
23
TanakaH.KamataN.YamadaA.EndoK.FujiiT.YoshinoT.et al (2018). ADJUST study group. Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn’s disease.J. Gastroenterol. Hepatol.331031–1038. 10.1111/jgh.14034
24
TorresJ.MehandruS.ColombelJ. F.Peyrin-BirouletL. (2017). Crohn’s disease.Lancet3891741–1755. 10.1016/S0140-6736(16)31711-1
25
UngaroR.MehandruS.AllenP. B.Peyrin-BirouletL.ColombelJ. F. (2017). Ulcerative colitis.Lancet3891756–1770. 10.1016/S0140-6736(16)32126-2
26
van der HeijdeD.RamiroS.LandeweR.BaraliakosX.Van den BoschF.SeprianoA.et al (2017). 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.Ann. Rheum. Dis.76978–991. 10.1136/annrheumdis-2016-210770
27
ZelinkovaZ.BultmanE.VogelaarL.BouzianeC.KuipersE. J.van der WoudeC. J. (2012). Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease.World J. Gastroenterol.186967–6973. 10.3748/wjg.v18.i47.6967
Summary
Keywords
spondyloarthritis, inflammatory bowel disease, sex differences, adalimumab, infliximab
Citation
Laganà B, Zullo A, Scribano ML, Chimenti MS, Migliore A, Picchianti Diamanti A, Lorenzetti R, Scolieri P, Ridola L, Ortona E, Pierdominici M and Bruzzese V (2019) Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. Front. Pharmacol. 10:47. doi: 10.3389/fphar.2019.00047
Received
28 September 2018
Accepted
15 January 2019
Published
28 January 2019
Volume
10 - 2019
Edited by
Maria Gerosa, University of Milan, Italy
Reviewed by
Claudio Ferrante, Università degli Studi G. d’Annunzio Chieti e Pescara, Italy; Ignazio Castagliuolo, University of Padua, Italy
Updates
Copyright
© 2019 Laganà, Zullo, Scribano, Chimenti, Migliore, Picchianti Diamanti, Lorenzetti, Scolieri, Ridola, Ortona, Pierdominici and Bruzzese.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Elena Ortona, elena.ortona@iss.it
†Senior authors
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.